The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

Trial Title: The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

NCT ID: NCT01447199

Condition: Bladder Cancer
Colorectal Cancer
Endometrial Cancer
Kidney Cancer
Skin Cancer
Uterus Cancer

Conditions: Official terms:
Colorectal Neoplasms
Urinary Bladder Neoplasms
Colonic Neoplasms
Endometrial Neoplasms
Kidney Neoplasms
Carcinoma, Renal Cell
Skin Neoplasms
Uterine Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Disease Susceptibility

Conditions: Keywords:
Bladder cancer
Colorectal cancer
Endometrial cancer
Kidney cancer
Skin cancer
Uterus cancer
Molecular Predisposition
Hereditary Nonpolyposis Colon Cancer
HNPCC
Molecular genetic testing
Gene mutations
Mutation analyses
Genetic polymorphisms
Family history of cancer
Early age of cancer onset
Little/no personal or family history of cancer
Spouses
Questionnaires
Blood sample
Saliva Sample

Study type: Observational

Overall status: Unknown status

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Behavioral
Intervention name: Health and Diet Questionnaire
Description: Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
Arm group label: Gene Mutation
Arm group label: No Cancer History
Arm group label: Spouses

Other name: Survey

Summary: The goal of this study is to understand factors which may influence risk for colorectal and other cancers in families. These factors include genetic variability, in combination with diet and lifestyle. In order to achieve these goals, we need to contact as many eligible participants as possible.

Detailed description: If you agree to take part in this study, you will have a single sample (8-10 teaspoons) of blood collected, depending upon current health status. The blood will be drawn at MD Anderson. If you cannot come to the clinic, a blood drawing kit will be sent to the your home, which will include instructions and a postage-paid return express mail envelope. Phlebotomy charges connected to this study will be paid by the study. The blood sample will be sent to a research laboratory at MD Anderson for analyses. If you are unwilling or unable to give a blood sample, you can give a saliva sample instead. In this case, a kit will be mailed to you with instructions for obtaining the saliva sample. A prepaid envelope will be included for its return. Participants who previously participated in Protocol PA11-0567 and provided a blood sample do not need to provide another blood sample. The previously stored blood sample collected by Protocol PA11-0567 may be used. You will be asked to answer a series of questions. These questions will ask about foods eaten either one year ago or one year before the first diagnosis of cancer. There will also be questions about cooking methods as well as overall health, and vitamin and medication use. Some of the questions are personal, but all answers will be kept strictly private. The questionnaire will be sent to your home via U.S. or express mail. It may take several hours to complete the survey, but there is no time limit on its completion. There are no right or wrong answers to the questions. A postage-paid return envelope will be provided for the return of the questionnaire. Solid tumor material and colonoscopy specimens of normal tissue will be collected from participants requiring either colonoscopy or surgery for routine clinical reasons. The tumor fragments will be collected from specimens. Tissue required for a clinical pathology diagnosis will not be used for research purposes. This is an investigational study. About 2,000 patients and family members will take part in this study. All will be enrolled at MD Anderson.

Criteria for eligibility:

Study pop:
Referrals from Departments of GI Oncology, GI Medicine and Nutrition, GI Surgery, GYN Oncology, Cancer Prevention and from the Genetic Counselors at UT MD Anderson Cancer Center, families and spouses.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: 1. All patients with a new referral for a diagnosis of colorectal cancer (adenocarcinoma) and/or HNPCC-related cancers at the UTMDACC will be considered potentially eligible for this study regardless of prior treatment. 2. Families maintained at the UTMDACC Hereditary Colon Cancer Registry that have a known germline mutation in a mismatch repair gene or contain two or more first degree relatives diagnosed with CRC and/or any HNPCC-related cancers, one of whom must be less than or equal to 50 years at diagnosis. 3. First-degree and more distant relatives of individuals diagnosed with CRC and/or any HNPCC-related cancers from either of the groups in 1 and 2 (above). 4. Any patient diagnosed with CRC and/or any HNPCC-related cancers less than or equal to 45 years of age. 5. Greater than or equal to age 18 at time of study. 6. Able to provide informed consent to participate in this study indicating that they are aware of the investigational nature, in keeping with the policies of this hospital. 7. Non-HNPCC quartets, defined as parents and two offspring who do not carry a mismatch repair gene mutation. These non-HNPCC quartets should have no personal history of cancer, nor cancer in any first degree relatives of the quartet members, nor history of trinucleotide repeat syndromes. Non-HNPCC parents in a quartet should be less than 34 years old at the time the offspring were born. 8. Lynch Syndrome patients identified and recruited through Protocol PA11-0567 who opt into Optional Procedure B, which consents the patient to participate in this study. Exclusion Criteria: 1. Diagnosis of current major psychiatric disorder, per DSM-III-R (or DSM IV). 2. Age less than 18 years at time of enrollment.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: Accepts Healthy Volunteers

Locations:

Facility:
Name: University of Texas MD Anderson Cancer Center

Address:
City: Houston
Zip: 77030
Country: United States

Start date: September 1994

Completion date: September 30, 2020

Lead sponsor:
Agency: M.D. Anderson Cancer Center
Agency class: Other

Source: M.D. Anderson Cancer Center

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT01447199
http://www.mdanderson.org